The National Biostimulant Industry Federation (NBIF) on Sunday called for urgent government intervention to address regulatory bottlenecks in the domestic market and high tariffs abroad, which are hampering the sector's growth potential.
NBIF urged the Prime Minister Narendra Modi's office to coordinate reforms across key ministries to support an industry valued at ₹40,000 crore and comprising over 5,000 small and medium enterprises.
Indian biostimulant exporters face tariffs of 15-28 per cent in key global markets, along with non-tariff barriers, including origin-specific efficacy trials and residue testing requirements, NBIF said in a statement.
The absence of mutual recognition agreements with major trading blocs, like the European Union and Asean, compounds these challenges.
Domestically, the industry is grappling with regulatory ambiguity and delays in product approvals under India's Fertiliser Control Order, with no dedicated testing protocols for natural substances like seaweed and humic acid.
"The industry doesn't need subsidies. What it needs is clear, science-driven, and industry-aligned regulation," NBIF President Rajit Choksi said.
India possesses significant natural advantages for biostimulant production, including a 7,500-kilometre coastline suitable for seaweed cultivation and lignite-rich regions for humic acid extraction.
Seaweed and humic-based products comprise over 70 per cent of the global USD 6.2 billion biostimulant market.
However, global companies are increasingly capturing India's domestic market, while local manufacturers struggle with regulatory clearances, according to NBIF Secretary General Sahil Malik.
The federation has proposed a series of policy reforms, including declaring biostimulants a strategic sector, establishing a national tariff strategy task force, and creating centralised testing facilities.
With appropriate reforms, India could expand its biostimulant market from Rs 4,000 crore to Rs 15,000 crore by 2030 while creating employment for over 1,00,000 agricultural workers and biotechnology professionals, NBIF said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)